The Mosaic Company’s Post

- Second quarter net loss of $162 million, Adjusted EBITDA of $584 million. - Phosphate production volumes increased almost 100,000 tonnes sequentially. -Significant progress made on cost saving initiatives. - Accelerating Mosaic Biosciences growth; achieved 5 million acres of coverage in North. and Central America in the 2024 crop year. -Year-to-date capital return to shareholders of $298 million, including $160 million of share repurchase.

This is a wide-ranging discussion, including some thoughts about the FOMC, the implications of higher immigration for growth and long-term R-star, and the near-term outlook for inflation and interest rates in the U.K.

Clients are at various stages of their transformation journeys, but the consensus is clear – digitalization, data management and analytics are all increasingly in focus, and there is a growing need to do more. To modernize and embrace the future, organizations must address the critical question: How can we update our systems to meet the demands of the digital age while ensuring seamless continuity? I look forward to hearing from leading FinTechs like Duco at CIBC Mellon’s Fintech Showcase tomorrow!.

Learn more about the Omni-Tract Speed-Tract. https://lnkd.in/gYeKWiZY

Here’s our 2024 forecast; what’s IN and OUT for the year ⤵⤵⤵

8 Things to Look for in a Quarterly Report - https://buff.ly/3XD6NEr

The Macro Minute | January 29, 2024 In today's video, I preview the implications of the Q1 QRA. You can watch it here: https://lnkd.in/eWkibaH9

Double check these numbers.

Today we release our Q3 financial results showing that despite continued market weakness, we are starting to turn the corner in many parts of the business, particularly in Network Infrastructure which saw a return to net sales growth and robust order intake. Learn more about our Q3 results: https://nokia.ly/4bQI6Yi #QComms

The Macro Minute | January 29, 2024 In today's video, I preview the implications of the Q1 QRA. You can watch it here: https://lnkd.in/eEkxUiS2